Dr Andrew Lewington
Renal Diseases Theme Lead, NIHR Diagnostic Evidence Co-operative Leeds


Dr Lewington is a Consultant Renal Physician and Honorary Associate Professor at Leeds Teaching Hospitals NHS Trust, where he is the clinical lead for AKI and a kidney transplant physician. He was an expert advisor to the NCEPOD Adding Insult to Injury AKI study and is the AKI lead for the Renal Association. He is the current Renal Association clinical guidelines chair and sits on the RA clinical affairs board. Dr Lewington chaired a multi professional group to produce the Academy of Medical Royal Colleges AKI core competencies. He is the UK Kidney Research Consortium lead for AKI and is working to facilitate AKI research in the UK. He was co-supervisor of the first Nephrology MRC awarded grant in West Yorkshire investigating markers of kidney transplant dysfunction. He is the West Yorkshire LCRN renal study lead and the Chief investigator on an NIHR Applied Programme to evaluate protein biomarkers in renal transplantation. He is chair of the NHS England AKI Risk Workstream. He was a member of the NICE AKI and intravenous clinical guideline groups. Dr Lewington is the co-chief investigator for the NIHR portfolio study investigating the role of recombinant alkaline phosphatase for treatment of AKI in sepsis (£29m). He is a chief investigator for the NIHR portfolio study assessing the outcomes of patients with acute kidney injury in critical care. He has worked with a range of companies providing the NGAL diagnostic assay for early prediction of AKI. He was recently successful in obtaining an HTA Grant to investigate the role of biomarkers in diagnosing acute kidney injury in patients with critical illness. Dr Lewington is co-chair of the Education Workstream for the International Society of Nephrology AKI 0 x 25 initiative.